Annovis Bio Inc (ANVS)

Oct 31, 2024

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio - GlobeNewswire

Oct 31, 2024

Oct 28, 2024

Annovis Bio, Inc. (NYSE:ANVS) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Oct 28, 2024

Oct 25, 2024

Annovis Bio (NYSE:ANVS) Raised to Buy at Maxim Group - MarketBeat

Oct 25, 2024

Oct 24, 2024

Annovis Bio to Present Key Alzheimer’s Research at CTAD Conference - MSN

Oct 24, 2024

Oct 24, 2024

Annovis Bio (NYSE: ANVS) Receives FDA Clearance to Initiate Pivotal Phase 3 Alzheimer’s Studies - Barchart

Oct 24, 2024

Oct 22, 2024

Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024 - The Manila Times

Oct 22, 2024

Oct 19, 2024

Annovis Bio files three drug patents - Pennsylvania Business Report

Oct 19, 2024

Oct 17, 2024

Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials (NYSE:ANVS) - Seeking Alpha

Oct 17, 2024

Oct 17, 2024

Annovis Bio To Continue Alzheimer's Disease Clinical Trials (NYSE:ANVS) - Seeking Alpha

Oct 17, 2024

Oct 17, 2024

Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug - Yahoo Finance

Oct 17, 2024

Oct 16, 2024

Annovis Bio shares hold Buy rating from HC Wainwright - Investing.com India

Oct 16, 2024

Oct 16, 2024

Annovis Bio Stock Surges As Analyst Reiterates ‘Buy’ On Alzheimer’s Drug Progress: Retail Stays Bullish - Barchart

Oct 16, 2024

Oct 16, 2024

Annovis Bio shares hold Buy rating from HC Wainwright By Investing.com - Investing.com UK

Oct 16, 2024

Oct 16, 2024

In the Green: Annovis Bio Inc (ANVS) Closes at 7.98, Up/Down 6.26 from Previous Day - The Dwinnex

Oct 16, 2024

Oct 16, 2024

Annovis Bio (NYSE:ANVS) Given Buy Rating at HC Wainwright - MarketBeat

Oct 16, 2024

Oct 16, 2024

(ANVS) Investment Analysis and Advice - Stock Traders Daily

Oct 16, 2024

Oct 15, 2024

Annovis Bio Advances Alzheimer’s Treatment with FDA Approval for Phase 3 Trials - MyChesCo

Oct 15, 2024

Oct 15, 2024

Annovis Bio (ANVS) Stock Soars After FDA Approval - Stocks Telegraph

Oct 15, 2024

Oct 15, 2024

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs - The Manila Times

Oct 15, 2024

Oct 15, 2024

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer’s Studies, Paving the Way to NDAs - GlobeNewswire

Oct 15, 2024

Oct 10, 2024

Freedom Village Hosts Successful Third Annual Walk to End Alzheimer’s - MyChesCo

Oct 10, 2024

Oct 05, 2024

(ANVS) On The My Stocks Page - Stock Traders Daily

Oct 05, 2024

Oct 04, 2024

Annovis Bio Inc (ANVS-N) QuotePress Release - The Globe and Mail

Oct 04, 2024

Oct 03, 2024

ANVSAnnovis Bio, Inc. Latest Stock News & Market Updates - StockTitan

Oct 03, 2024

Oct 03, 2024

Brookline Capital Initiates Coverage of Annovis Bio (ANVS) with Buy Recommendation - MSN

Oct 03, 2024

Oct 03, 2024

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases - ForexTV.com

Oct 03, 2024

Oct 03, 2024

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for ... - The Bakersfield Californian

Oct 03, 2024

Oct 03, 2024

Annovis Bio, Inc. (NYSE:ANVS) Receives Average Rating of "Buy" from Analysts - MarketBeat

Oct 03, 2024

Oct 03, 2024

BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD - MSN

Oct 03, 2024

Oct 02, 2024

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations - The Manila Times

Oct 02, 2024

Oct 02, 2024

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential - GlobeNewswire

Oct 02, 2024

Oct 02, 2024

19,907 Shares in Annovis Bio, Inc. (NYSE:ANVS) Bought by XTX Topco Ltd - Defense World

Oct 02, 2024

Oct 02, 2024

Annovis Bio Files Patents for Innovative Therapies in Neurodegenerative Disease Treatment - MSN

Oct 02, 2024

Oct 01, 2024

Annovis Bio stock outlook supported by innovative neurodegenerative therapies - Investing.com India

Oct 01, 2024

Oct 01, 2024

Annovis Bio: Against The Grain In Alzheimer's Disease - Life Science Leader Magazine

Oct 01, 2024

Oct 01, 2024

Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition - cnhinews.com

Oct 01, 2024

Oct 01, 2024

Annovis Bio (NYSE:ANVS) Rating Reiterated by HC Wainwright - MarketBeat

Oct 01, 2024

Sep 30, 2024

Annovis Bio files three new patents for combination therapies - TipRanks

Sep 30, 2024

Sep 30, 2024

Annovis Bio files patents for neurodegenerative treatment combos - Investing.com

Sep 30, 2024

Sep 30, 2024

Annovis Bio Files Patents for Neurodegenerative Combination Therapies - TipRanks

Sep 30, 2024

Sep 30, 2024

Annovis Files Three New Patents for Combination Therapies Involving Buntanetap, Trulicity, and Viagra - GlobeNewswire

Sep 30, 2024

Sep 27, 2024

Annovis Bio: Progress With Buntanetap In Parkinson's Disease, But Cash Runway Concerns Loom - Seeking Alpha

Sep 27, 2024

Sep 26, 2024

Anavex Lf SC (AVXL-Q) QuotePress Release - The Globe and Mail

Sep 26, 2024

Sep 26, 2024

Longeveron Inc (LGVN-Q) QuotePress Release - The Globe and Mail

Sep 26, 2024

Sep 24, 2024

(ANVS) Long Term Investment Analysis - Stock Traders Daily

Sep 24, 2024

Sep 18, 2024

Passage Bio Shares Promising Data on PBFT02 for Frontotemporal Dementia - MyChesCo

Sep 18, 2024